HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives.
To view the full press release, visit https://ibn.fm/guMCF
At a glance
- Company
- HeartBeam, Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Earnings
Key figures
- First-quarter 2026 net loss
- $4.7 million
- Net loss in prior-year period
- $5.5 million
- April offering gross proceeds
- $11.5 million
- Issued patents
- over 20
Products and programs
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.
(1)Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What financial results did HeartBeam report for the first quarter of 2026?
HeartBeam reported a first-quarter net loss of $4.7 million, compared with a $5.5 million net loss in the prior-year period. The release also said research and development expenses declined year over year. It did not provide further expense figures or a breakdown of the results in the summary provided.
What did HeartBeam say about its April 2026 public offering?
The release said an April public offering generated $11.5 million in gross proceeds. It did not give details in the summary about the securities offered, the offering price, or how the company plans to use the proceeds.
What is a 12-lead ECG, and how can signals from three directions be used to create one?
An ECG records the heart’s electrical activity. A 12-lead ECG presents that activity from multiple perspectives, helping clinicians assess cardiac rhythm and other patterns. ECG systems can derive or synthesize a 12-lead view from signals collected using fewer electrodes or directions, though the method and its intended clinical use depend on the specific technology.
What does FDA clearance mean for a medical device?
FDA clearance generally means the agency has reviewed a device submission and found the device suitable for marketing for a specified intended use. It is not a blanket authorization for every possible use. The cleared indications describe the purposes and conditions for which the device is intended to be used.
SEC filings
- 10-QQuarterly report Filed
- 4/A4/A Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 4Insider transaction Filed
- 8-KCURRENT REPORT Filed
- 424B5PROSPECTUS SUPPLEMENT Filed
- 424B5PROSPECTUS SUPPLEMENT Filed
Earlier from HeartBeam, Inc.
- HeartBeam (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients
- HeartBeam (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates
- HeartBeam (NASDAQ: BEAT) Closes $10M Public Offering to Advance Cardiac Technology Commercialization
- HeartBeam (NASDAQ: BEAT) Launches Proposed Public Offering to Support Commercialization and AI Initiatives
- HeartBeam’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article
